Women’s-health-focused pharma Organon is grabbing exclusive global licensing rights to Sebela Pharmaceuticals’ newly approved hormone-free copper intrauterine device in a deal potentially worth more than $532 million.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
Women’s-health-focused pharma Organon is grabbing exclusive global licensing rights to Sebela Pharmaceuticals’ newly approved hormone-free copper intrauterine device in a deal potentially worth more than $532 million.